O64 EFFECT OF BASELINE NS5A POLYMORPHISMS ON VIROLOGIC RESPONSE TO THE ALL-ORAL COMBINATION OF DACLATASVIR + SOFOSBUVIR ± RIBAVIRIN IN PATIENTS WITH CHRONIC HCV INFECTION

MLA

J. Chiarella, et al. “O64 Effect of Baseline Ns5a Polymorphisms on Virologic Response to the All-Oral Combination of Daclatasvir + Sofosbuvir ± Ribavirin in Patients with Chronic Hcv Infection.” Journal of Hepatology, vol. 60, Apr. 2014, pp. S26–27. EBSCOhost, https://doi.org/10.1016/s0168-8278(14)60066-0.

APA

J. Chiarella, M. Kozal, Nannan Zhou, X. Yang, D. Hernandez, & F. McPhee. (2014). O64 Effect of Baseline Ns5a Polymorphisms on Virologic Response to the All-Oral Combination of Daclatasvir + Sofosbuvir ± Ribavirin in Patients with Chronic Hcv Infection. Journal of Hepatology, 60, S26–S27. https://doi.org/10.1016/s0168-8278(14)60066-0

Chicago

J. Chiarella, M. Kozal, Nannan Zhou, X. Yang, D. Hernandez, and F. McPhee. 2014. “O64 Effect of Baseline Ns5a Polymorphisms on Virologic Response to the All-Oral Combination of Daclatasvir + Sofosbuvir ± Ribavirin in Patients with Chronic Hcv Infection.” Journal of Hepatology 60 (April): S26–27. doi:10.1016/s0168-8278(14)60066-0.